Glasgow prognostic score as a predictor of decompensation in patients with primary biliary cholangitis

Table 2 Comparison of baseline clinical characteristics, n (%)/median interquartile range

Characteristic	Total (n = 762)	Decompensation (n = 113)	Non-decompensation (n = 649)	P value
Age (years)	56 (49-66)	57 (50-70.5)	56 (49-65)	0.112
Sex				0.973
Female	606 (79.5)	90 (79.6)	516 (79.5)
Male	156 (20.5)	23 (20.4)	133 (20.5)
BMI (kg/m2)	22.06 (20.02-24.22)	21.50 (19.95-23.90)	22.06 (20.04-24.38)	0.222
Hypertension				0.974
Yes	183 (24)	27 (23.9)	156 (24)
No	579 (76)	86 (76.1)	493 (76)
Diabetes mellitus				0.898
Yes	85 (11.2)	13 (11.5)	72 (11.1)
No	677 (88.8)	100 (88.5)	577 (88.9)
Atherosclerosis				0.990
Yes	47 (6.2)	7 (6.2)	40 (6.2)
No	715 (93.8)	106 (93.8)	609 (93.8)
TBIL (μmol/L)	18.4 (12.4-40.08)	27.1 (12.65-80.6)	17.8 (12.35-35)	0.002
ALT (U/L)	53.5 (28-106)	63 (29.1-111.5)	52 (28-104)	0.249
AST (U/L)	54 (33-103.93)	75 (37.85-119)	50 (32-98.95)	0.002
ALP (U/L)	176.15 (113-320)	252 (139.75-440.5)	171 (108.5-285)	< 0.001
GGT (U/L)	205 (71-415.75)	253 (104-521.5)	196 (68-404.5)	0.011
INR	1 (0.94-1.09)	1.01 (0.91-1.13)	1 (0.94-1.09)	0.737
GLOB (g/L)	33.15 (29-37.6)	32.5 (28.5-39.05)	33.2 (29-37.5)	0.829
ALB (g/L)	37.9 (33.5-42)	34 (29.5-38.4)	38.4 (34.2-42.2)	< 0.001
CRP (mg/L)	2.47 (1.1-7.35)	10.8 (3.63-12.75)	1.97 (1.02-5)	< 0.001
MELD score	3.86 (1.53-7.34)	5.57 (2.16-9.13)	3.67 (1.48-6.79)	0.007
AMA-M2				0.877
1	528 (69.3)	79 (69.9)	449 (69.2)
0	234 (30.7)	34 (30.1)	200 (30.8)
SP100				0.623
1	84 (11.1)	14 (12.4)	70 (10.8)
0	676 (88.9)	99 (87.6)	577 (89.2)
GP210				0.361
1	164 (21.5)	28 (24.8)	136 (21)
0	598 (78.5)	85 (75.2)	513 (79)
Paris I				0.001
Response	495 (65)	58 (51.3)	437 (67.3)
Suboptimal response	267 (35)	55 (48.7)	212 (32.7)
Paris II				0.011
Response	319 (41.9)	35 (31)	284 (43.8)
Suboptimal response	443 (58.1)	78 (69)	365 (56.2)
Mayo	4 (3-5)	5 (4-6)	4 (3-5)	< 0.001
GLOBE				< 0.001
> 0.3	133 (17.5)	37 (32.7)	96 (14.8)
≤ 0.3	629 (82.5)	76 (67.3)	553 (85.2)
UK-PBC	0.57 (-0.32 to 1.98)	1.49 (0.26-3.10)	0.46 (-0.40 to 1.77)	< 0.001
GPS				< 0.001
0	475 (62.3)	26 (23.0)	449 (69.2)
1	198 (26.0)	49 (43.4)	149 (23.0)
2	89 (11.7)	38 (33.6)	51 (7.8)
mGPS				< 0.001
0	616 (80.8)	51 (45.1)	565 (87.1)
1	58 (7.6)	24 (21.3)	34 (5.2)
2	88 (11.6)	38 (33.6)	50 (7.7)
hs-mGPS				< 0.001
0	445 (58.4)	27 (23.9)	418 (64.4)
1	166 (21.8)	36 (31.9)	130 (20.0)
2	151 (19.8)	50 (44.2)	101 (15.6)

ALB: Albumin; ALP: Alkaline phosphatase; ALT: Alanine aminotransferase; AMA-M2: Anti-mitochondrial antibody M2; AST: Aspartate aminotransferase; BMI: Body mass index; CRP: C-reactive protein; GGT: Gamma-glutamyl transferase; GLOB: Globulin; GP210: Anti-glycoprotein 210 antibody; GPS: Glasgow prognostic score; hs-mGPS: High-sensitivity modified Glasgow prognostic score; INR: International normalized ratio; MELD: Model for end-stage liver disease; mGPS: Modified Glasgow prognostic score; SP100: Anti-nuclear dot protein SP100 antibody; TBIL: Total bilirubin; UK-PBC: United Kingdom-primary biliary cholangitis.